RLAY

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

2.900

Open

2.800

VWAP

2.84

Vol

1.28M

Mkt Cap

481.76M

Low

2.750

Amount

3.65M

EV/EBITDA(TTM)

Total Shares

132.74M

-232.02M

EV/OCF(TTM)

P/S(TTM)

55.39

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.476

-31%

-0.471

-25.17%

-0.438

-2.66%

Estimates Revision

The market is revising Upward the revenue expectations for Relay Therapeutics, Inc. (RLAY) for FY2025, with the revenue forecasts being adjusted by 9.95% over the past three months. During the same period, the stock price has changed by -28.32%.

Revenue Estimates for FY2025

Revise Upward

+9.95%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-20.71%

In Past 3 Month

Stock Price

Go Down

-28.32%

In Past 3 Month

11 Analyst Rating

418.15% Upside

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 14.56 USD with a low forecast of 4.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

2 Hold

0 Sell

Strong Buy

418.15% Upside

Current: 2.810

Low

4.00

Averages

14.56

High

23.00

418.15% Upside

Current: 2.810

Low

4.00

Averages

14.56

High

23.00

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$16

2025-03-07

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$16

2025-03-07

Reiterates

Strong Buy

Reason

Stifel

Bradley Canino

Strong Buy

Maintains

$27 → $23

2025-02-27

Reason

Stifel

Bradley Canino

Price Target

$27 → $23

2025-02-27

Maintains

Strong Buy

Reason

Goldman Sachs

Salveen Richter

Strong Buy

Maintains

$20 → $18

2025-02-27

Reason

Goldman Sachs

Salveen Richter

Price Target

$20 → $18

2025-02-27

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$16

2025-01-14

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$16

2025-01-14

Reiterates

Strong Buy

Reason

JMP Securities

Silvan Tuerkcan

Buy

Reiterates

$21

2024-12-12

Reason

JMP Securities

Silvan Tuerkcan

Price Target

$21

2024-12-12

Reiterates

Buy

Reason

Leerink Partners

Christopher Liu

Buy

Maintains

$19 → $18

2024-12-04

Reason

Leerink Partners

Christopher Liu

Price Target

$19 → $18

2024-12-04

Maintains

Buy

Reason

Leerink analyst Christopher Liu lowered the firm's price target on Relay Therapeutics to $18 from $19 and keeps an Outperform rating on the shares after the company announced that lirafugratinib will be out licensed to Elevar Therapeutics. Recall, the company had previously announced its decision to seek a global commercial partner for lirafugratinib during a company event in September 2024. Overall, Leerink thinks this decision is a prudent use of resources given the relatively small size of FGFR2+ populations.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Relay Therapeutics Inc (RLAY.O) is -1.62, compared to its 5-year average forward P/E of -8.97. For a more detailed relative valuation and DCF analysis to assess Relay Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.97

Current PE

-1.62

Overvalued PE

0.12

Undervalued PE

-18.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.18

Current EV/EBITDA

0.62

Overvalued EV/EBITDA

1.77

Undervalued EV/EBITDA

-14.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

953.13

Current PS

92.72

Overvalued PS

2232.51

Undervalued PS

-326.25